GBS
MCID: GLL022
MIFTS: 59

Guillain-Barre Syndrome (GBS)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Guillain-Barre Syndrome

MalaCards integrated aliases for Guillain-Barre Syndrome:

Name: Guillain-Barre Syndrome 12 52 25 58 36 54 42 43 15 17 71
Guillain-Barré Syndrome 74 52 25 53 3 32
Fisher Syndrome 25 53 36
Gbs 52 25 58
Acute Inflammatory Demyelinating Polyneuropathy 52 71
Acute Inflammatory Polyneuropathy 52 25
Acute Inflammatory Demyelinating Polyradiculoneuropathy 52
Acute Autoimmune Peripheral Neuropathy 52
Landry-Guillain-Barre-Strohl Syndrome 52
Acute Immune-Mediated Polyneuropathy 52
Acute Postinfectious Polyneuropathy 12
Variant of Guillain-Barre Syndrome 58
Guillain-Barré-Strohl Syndrome 52
Landry-Guillain-Barre Syndrome 25
Guillain-Barre-Strohl Syndrome 58
Acute Inflammatory Neuropathy 52
Acute Infectious Polyneuritis 25
Acute Infective Polyneuritis 12
Post-Infectious Polyneuritis 12
Landry's Ascending Paralysis 52
Postinfectious Polyneuritis 12
Post-Infective Polyneuritis 52
Miller Fisher Syndrome 71
Infectious Neuronitis 12
Variant of Gbs 58

Characteristics:

Orphanet epidemiological data:

58
guillain-barre syndrome
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;
variant of guillain-barre syndrome
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:12842
MeSH 43 D020275
NCIt 49 C116345
SNOMED-CT 67 40956001
ICD10 32 G61.0
MESH via Orphanet 44 D020275
ICD10 via Orphanet 33 G61.0
UMLS via Orphanet 72 C0018378
UMLS 71 C0018378 C0393799 C3542501

Summaries for Guillain-Barre Syndrome

Genetics Home Reference : 25 Guillain-Barré syndrome is an autoimmune disorder that affects the nerves. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In Guillain-Barré syndrome, the immune response damages peripheral nerves, which are the nerves that connect the central nervous system (the brain and spinal cord) to the limbs and organs. Specifically, the immune response affects a particular part of peripheral nerves called axons, which are the extensions of nerve cells (neurons) that transmit nerve impulses. Guillain-Barré syndrome can affect the neurons that control muscle movement (motor neurons); the neurons that transmit sensory signals such as pain, temperature, and touch (sensory neurons); or both. As a result, affected individuals can experience muscle weakness or lose the ability to feel certain sensations. Muscle weakness or paralysis are the characteristic features of Guillain-Barré syndrome. The weakness often begins in the legs and spreads to the arms, torso, and face and is commonly accompanied by numbness, tingling, or pain. Additional signs and symptoms of the condition include difficulty swallowing and difficulty breathing. Occasionally, the nerves that control involuntary functions of the body such as blood pressure and heart rate are affected, which can lead to fluctuating blood pressure or an abnormal heartbeat (cardiac arrhythmia). There are several types of Guillain-Barré syndrome, classified by the part of the peripheral nerve involved in the condition. The most common type of Guillain-Barré syndrome is acute inflammatory demyelinating polyradiculoneuropathy (AIDP). In AIDP, the immune response damages myelin, which is the covering that protects axons and promotes the efficient transmission of nerve impulses. In two other types of Guillain-Barré syndrome, acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN), the axons themselves are damaged by the immune response. In AMAN, only the axons of motor neurons are damaged. In AMSAN, the axons of sensory neurons are also damaged. Because of sensory nerve damage, affected individuals can lose the ability to sense the position of their limbs and can have abnormal or absent reflexes (areflexia). Miller Fisher syndrome, another type of Guillain-Barré syndrome, involves cranial nerves, which extend from the brain to various areas of the head and neck. Miller Fisher syndrome is characterized by three features: weakness or paralysis of the muscles that move the eyes (ophthalmoplegia), problems with balance and coordination (ataxia), and areflexia. People with this condition can have other signs and symptoms common in Guillain-Barré syndrome, such as muscle weakness. Guillain-Barré syndrome occurs in people of all ages. The development of the condition usually follows a pattern. Prior to developing the condition, most people with Guillain-Barré syndrome have a bacterial or viral infection. The first phase of Guillain-Barré syndrome, during which signs and symptoms of the condition worsen, can last up to four weeks, although the peak of the illness is usually reached in one to two weeks. During the second phase, called the plateau, signs and symptoms of Guillain-Barré syndrome stabilize. This phase can last weeks or months. During the recovery phase, symptoms improve. However, some people with Guillain-Barré syndrome never fully recover and can still experience excessive tiredness (fatigue), muscle weakness, or muscle pain.

MalaCards based summary : Guillain-Barre Syndrome, also known as guillain-barré syndrome, is related to pharyngeal-cervical-brachial variant of guillain-barre syndrome and miller fisher syndrome, and has symptoms including seizures, tremor and back pain. An important gene associated with Guillain-Barre Syndrome is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Measles and Herpes simplex virus 1 infection. The drugs 4-Aminopyridine and Interferon beta-1a have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and spinal cord, and related phenotypes are cellular and homeostasis/metabolism

Disease Ontology : 12 An autoimmune disease of peripheral nervous system that causes body's immune system to attack part of the peripheral nervous system.

NIH Rare Diseases : 52 Guillain-Barre syndrome (GBS) is a rare syndrome in which the body's immune system attacks part of the peripheral nervous system . The peripheral nervous system carries signals from the brain to the muscles. Symptoms of GBS include muscle weakness, numbness, and tingling sensations, which can increase in intensity until the muscles cannot be used at all (paralysis ). The exact cause of Guillain-Barre syndrome is unknown. In most cases, GBS occurs a few days or weeks after symptoms of a viral infection. In rare cases, GBS may run in families. A diagnosis of GBS is suspected when a person has symptoms suggestive of the syndrome. A variety of tests, including a spinal tap , may be completed to confirm the diagnosis. Treatment options may include plasma exchange (plasmapheresis) and immunoglobulin therapy .

MedlinePlus : 42 Guillain-Barre syndrome is a rare disorder that causes your immune system to attack your peripheral nervous system (PNS). The PNS nerves connect your brain and spinal cord with the rest of your body. Damage to these nerves makes it hard for them to transmit signals. As a result, your muscles have trouble responding to your brain. No one knows what causes the syndrome. Sometimes it is triggered by an infection, surgery, or a vaccination. The first symptom is usually weakness or a tingling feeling in your legs. The feeling can spread to your upper body. In severe cases, you become almost paralyzed. This is life-threatening. You might need a respirator to breathe. Symptoms usually worsen over a period of weeks and then stabilize. Guillain-Barre can be hard to diagnose. Possible tests include nerve tests and a spinal tap. Most people recover. Recovery can take a few weeks to a few years. Treatment can help symptoms, and may include medicines or a procedure called plasma exchange. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Guillain-Barré (Ghee-YAN Bah-RAY) syndrome (GBS) is a rare, autoimmune disorder in which a person's own immune system damages the nerves, causing muscle weakness and sometimes paralysis. GBS can cause symptoms that last for a few weeks to several years. Most people recover fully, but some have permanent nerve damage. Some people have died of GBS.

NINDS : 53 Miller Fisher syndrome is a rare, acquired nerve disease that is considered to be a variant of Guillain-Barré syndrome. It is characterized by abnormal muscle coordination, paralysis of the eye muscles, and absence of the tendon reflexes. Like Guillain-Barré syndrome, symptoms may be preceded by a viral illness. Additional symptoms include generalized muscle weakness and respiratory failure. The majority of individuals with Miller Fisher syndrome have a unique antibody that characterizes the disorder.

KEGG : 36 Fisher syndrome is a variant of the Guillain- Barre syndrome (GBS) and its classical clinical triad consists of ophthalmoplegia, ataxia, and areflexia. It is a relatively rare neurological disorder, accounting for approximately 5% of acute inflammatory polyneuropathies. This disease is an immune-mediated condition and specific anti-ganglioside antibodies, especially IgG anti-GQ1b antibodies, are found in over 80% of the patients. Campylobacter and Haemophilus influenzae have been reported as infectious agents prior to the onset of Fisher syndrome. It has been reported that the median period required for the disappearance of ataxia was about 1 month, without therapy.

Wikipedia : 74 Guillain-Barre syndrome (GBS) is a rapid-onset muscle weakness caused by the immune system damaging the... more...

Related Diseases for Guillain-Barre Syndrome

Diseases in the Guillain-Barre Syndrome family:

Guillain-Barre Syndrome, Familial

Diseases related to Guillain-Barre Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1024)
# Related Disease Score Top Affiliating Genes
1 pharyngeal-cervical-brachial variant of guillain-barre syndrome 34.8 HP ACP1
2 miller fisher syndrome 34.1 TNF PMP22 CD40LG
3 chronic inflammatory demyelinating polyradiculoneuropathy 33.1 PMP22 MPZ MBP HLA-DRB1 ALB
4 polyneuropathy 32.5 TNF PMP22 MPZ MBP CD40LG ALB
5 demyelinating polyneuropathy 31.7 PMP22 HP ALB
6 polyradiculoneuropathy 31.6 PMP22 PMP2 MPZ MBP HLA-DRB1 CD40LG
7 peripheral nervous system disease 31.5 TNF PMP22 MPZ MOG MBP CD40LG
8 foot drop 31.3 PMP22 MPZ
9 polyradiculopathy 31.0 TNFRSF1B TNF PMP22 CD40LG
10 hereditary neuropathies 31.0 PMP22 MPZ MBP
11 hepatitis a 31.0 TNF HP ALB
12 hepatitis e 30.8 TNF CD40LG ALB
13 chickenpox 30.7 TNFRSF1B TNF CD40LG ALB
14 proteasome-associated autoinflammatory syndrome 1 30.7 TNFRSF1B TNF ALB
15 dengue disease 30.7 TNF CD40LG ALB
16 visceral leishmaniasis 30.7 TNF HLA-DRB1 ALB
17 neurilemmoma 30.6 PMP22 MPZ MBP
18 hydrocephalus due to congenital stenosis of aqueduct of sylvius 30.6 TH MBP
19 chronic polyneuropathy 30.6 PMP22 CD40LG
20 filariasis 30.5 TNFRSF1B TNF ALB
21 purpura 30.5 TNF CD79A CD40LG
22 exanthem 30.5 TNFRSF1B TNF CD40LG ALB
23 q fever 30.5 TNFRSF1B TNF CD40LG
24 membranous nephropathy 30.5 TNF HLA-DQA1 CD79A ALB
25 acute cystitis 30.4 TNF CD40LG ALB
26 endocarditis 30.4 TNFRSF1B TNF ALB
27 glomerular disease 30.4 CD79A ALB
28 leptospirosis 30.4 TNF HLA-DRB1 CD40LG
29 brachial plexus neuropathy 30.4 PMP22 MPZ CD40LG
30 allergic encephalomyelitis 30.4 MOG MBP
31 autoimmune neuropathy 30.3 PMP22 MPZ CD40LG
32 alcoholic hepatitis 30.3 TNFRSF1B TNF ALB
33 scarlet fever 30.3 TNF CD40LG ALB
34 mononeuritis multiplex 30.3 TNFRSF1B PMP22 CD40LG
35 nervous system disease 30.3 TNF MOG MBP ALB
36 herpes zoster 30.3 TNFRSF1B TNF HLA-DRB1 CD40LG
37 mononeuropathy 30.3 TNFRSF1B TNF PMP22 MPZ CD40LG
38 sensory peripheral neuropathy 30.3 PMP22 MPZ CD40LG ALB
39 hantavirus hemorrhagic fever with renal syndrome 30.3 TNF CD40LG ALB
40 microscopic polyangiitis 30.3 TNF HLA-DRB1
41 spondyloarthropathy 1 30.2 TNFRSF1B TNF HP CD40LG
42 anuria 30.2 HP CD40LG ALB
43 vasculitis 30.2 TNFRSF1B TNF CD79A CD40LG
44 pericarditis 30.2 TNF CD40LG ALB
45 parotitis 30.2 CD79A CD40LG ALB
46 pulmonary tuberculosis 30.2 TNF HP HLA-DRB1 HLA-DQB1 ALB
47 mumps 30.2 TNFRSF1B TNF HLA-DRB1 HLA-DQB1 CD40LG
48 keratoconjunctivitis sicca 30.2 CD79A CD40LG ALB
49 bacterial pneumonia 30.1 TNF CD40LG ALB
50 lipoid nephrosis 30.1 CD79A CD40LG ALB

Graphical network of the top 20 diseases related to Guillain-Barre Syndrome:



Diseases related to Guillain-Barre Syndrome

Symptoms & Phenotypes for Guillain-Barre Syndrome

UMLS symptoms related to Guillain-Barre Syndrome:


seizures, tremor, back pain, ophthalmoplegia, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, cerebellar ataxia, neuralgia

MGI Mouse Phenotypes related to Guillain-Barre Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 ACP1 ALB CD40LG CD79A FAS HLA-DQB1
2 homeostasis/metabolism MP:0005376 10.27 ACP1 ALB CD40LG CD79A DAAM2 FAS
3 cardiovascular system MP:0005385 10.22 ACP1 ALB CD40LG DAAM2 FAS HCRT
4 growth/size/body region MP:0005378 10.21 ACP1 DAAM2 FAS HCRT HLA-DQB1 MBP
5 hematopoietic system MP:0005397 10.14 CD40LG CD79A FAS HLA-DQA1 HLA-DQB1 HP
6 immune system MP:0005387 10.13 ACP1 ALB CD40LG CD79A FAS HLA-DQA1
7 liver/biliary system MP:0005370 9.86 ALB CD79A FAS HLA-DQB1 HP TH
8 muscle MP:0005369 9.81 ACP1 ALB DAAM2 HCRT HLA-DQB1 MOG
9 neoplasm MP:0002006 9.5 ALB CD79A FAS HP TH TNF
10 nervous system MP:0003631 9.44 CD40LG CD79A FAS HCRT HLA-DQB1 MBP

Drugs & Therapeutics for Guillain-Barre Syndrome

Drugs for Guillain-Barre Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
4-Aminopyridine Approved Phase 2 504-24-5 1727
2
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
3
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
4 Complement System Proteins Phase 2
5 Immunoglobulins Phase 2
6 Antibodies Phase 2
7 Immunoglobulins, Intravenous Phase 2
8 Pharmaceutical Solutions Phase 2
9 Rho(D) Immune Globulin Phase 2
10 gamma-Globulins Phase 2
11 Potassium Channel Blockers Phase 2
12 Anti-Infective Agents Phase 2
13 Adjuvants, Immunologic Phase 2
14 Antiviral Agents Phase 2
15 interferons Phase 2
16 Interferon-beta Phase 2
17 Hormone Antagonists Phase 2
18 Anti-Inflammatory Agents Phase 2
19 glucocorticoids Phase 2
20 Antineoplastic Agents, Hormonal Phase 2
21 Hormones Phase 2
22
Sodium citrate Approved, Investigational 68-04-2
23
Thiamine Approved, Investigational, Nutraceutical, Vet_approved 70-16-6, 59-43-8 1130
24
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
25
Calcium Approved, Nutraceutical 7440-70-2 271
26 Vitamins
27 Vitamin B Complex
28 Thiamin
29 Immunologic Factors
30 Hemostatics
31 Citrate
32 Chelating Agents
33 Anticoagulants
34 Calcium, Dietary
35 Coagulants
36 Immunoglobulin G
37 Vaccines
38 Autoantibodies

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome Completed NCT02342184 Phase 3 GB-0998
2 Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome Completed NCT02221271 Phase 3 NPB-01
3 Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study Unknown status NCT02029378 Phase 2 Eculizumab
4 Efficacy and Safety of Preventive Mechanical Ventilation in Adults With Guillain Barré Syndrome Completed NCT00167622 Phase 2
5 Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome Patients in Bangladesh: A Safety and Feasibility Study Completed NCT02780570 Phase 2
6 Assessment of Chronic GBS Improvement With Use of 4-AP Completed NCT00056810 Phase 2 4-aminopyridine (4-AP)
7 A PROSPECTIVE, MULTI-CENTER, PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH GUILLAIN-BARRÉ SYNDROME Completed NCT02493725 Phase 2 Eculizumab;Placebo
8 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of AVONEX When Used in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
9 Effect of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure With Immunological Causes Completed NCT03174964 Phase 2 IVIg
10 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
11 Early Onset Immunotherapy by Intravenous Immunoglobulin in Well-characterized Onconeural-antibody-positive Paraneoplastic Neurological Syndromes Completed NCT02343211 Phase 2 Immunoglobulin
12 A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal Completed NCT01856205 Phase 2 Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
13 A Phase 1b Study to Evaluate the Safety, Tolerability and Drug-Drug Interactions of ANX005 and Intravenous Immunoglobulin (IVIg) in Subjects With Guillain Barré Syndrome Recruiting NCT04035135 Phase 1, Phase 2 ANX005;Intravenous immunoglobulin
14 An Open-label, Single Arm, Multi-centre, Phase II Study Investigating Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of Imlifidase in Patients With Guillain-Barré Syndrome, in Comparison With Matched Control Patients Recruiting NCT03943589 Phase 2 Imlifidase
15 Phase I, Placebo-Controlled, Double-Blind Study To Evaluate The Safety, Tolerability, AND Immunogenicity Of GLS-5700, Administered ID Followed By Electroporation In Dengue Virus-Seropositive Adults Completed NCT02887482 Phase 1
16 Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults Completed NCT02809443 Phase 1
17 Phase I Trial To Evaluate The Safety Of CK0801 In Treatment-Resistant Guillain-Barré Syndrome (GBS) Not yet recruiting NCT03773328 Phase 1
18 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858
19 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
20 Feasibility of Two Novel Interactive Software Modules for the Rehabilitation of Patients With Neuromuscular Upper Limb Impairments Using the YouGrabber Training System — the KAYO Study Protocol Unknown status NCT03268304
21 The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation Unknown status NCT00173199
22 Change of Nerve Conduction Properties in IVIg Dependent Neuropathies Unknown status NCT01655394
23 Detection of Peripheral Blood Biomarkers in Intermediate Phase Spinal Cord Injury: Correlation With Neurological and Functional Outcomes, and Comparison to Other Central and Peripheral Neurological Conditions. Unknown status NCT01516385
24 Evaluating the B1 Status in Eating Disorder Female Adolescent Patients Unknown status NCT02164487
25 The Safety of GSK Biological's H1N1 Pandemic Vaccine in Manitoba, Canada Unknown status NCT01421251
26 Improving Influenza Vaccination Rates in Nurses Through Electronic Text Message Reminders : a Randomised Controlled Trial Unknown status NCT02589574
27 Effects of Robotic-assisted Gait Training In Non-Ambulatory Patients After Guillain-Barré Syndrome : A Randomized Controlled Trial Completed NCT02883270
28 Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome. Completed NCT01024088
29 Risk of Guillain-Barré Syndrome Following Meningococcal Conjugate (MCV4) Vaccination Completed NCT00575653
30 Comparison of Intravenous Immunoglobulin and Plasma Exchange in Treatment of Mechanically Ventilated Children With Guillain Barre Syndrome. A Randomized Study. Completed NCT01306578 IVIG
31 A Feasibility Study for Daily Use of a Brain Computer Interface for Communication in an ICU Completed NCT01005524
32 The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat) Completed NCT03710278
33 Regional Citrate Anticoagulation in Plasma Exchange Treatment Completed NCT01370200
34 Cervarix Long-term Safety Surveillance Using the PGRx Information System (PGRx Study) Completed NCT01498627
35 A Phase IV Study to Assess the Safety of Menveo Vaccine Being Used by HMO Subjects Aged 11-21 Years of Age Completed NCT01452464
36 Phase 4 Study of Post-License Safety Evaluation of Influenza Split Vaccine Completed NCT02136017
37 A Post-marketing Study to Monitor the Safety of Beijing Tiantan Biological's Influenza Virus Vaccine Administered in Chinese Subjects Aged 60 Years or Older Completed NCT01906593
38 Short and Long-Term Electronic Surveillance of a Large Number of Healthcare Workers Following Administration of an Adjuvanted Ph1n1 Vaccine Completed NCT01289418
39 A Post-marketing Safety Study of SIBP's Inactivated, Split-virion Influenza Vaccine Administered in Chinese Subjects Aged 3 Years and Older Completed NCT02133456
40 Active Surveillance of Adverse Events Following Immunization Among Healthcare Workers Immunized With the Influenza Vaccine Completed NCT01318876
41 Recovery of Visual Acuity in Vestibular Deficits Completed NCT00411216
42 Randomized Evaluation of Live Attenuated vs.Trivalent Inactivated Influenza Vaccines in Schools (RELATIVES)Pilot Study Completed NCT01995851
43 Pilot Project on Clinical Tolerance to a Live Attenuated Vaccine Against Influenza (Flumist®) in the Context of Influenza Vaccination in a Population Allergic to Eggs. Completed NCT02142491
44 International GBS Outcome Study (IGOS): A Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS). Recruiting NCT01582763
45 A Prospective Interventional Study to Investigate Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation With or Without Coagulation Factors Replacement Recruiting NCT03801135 Fibrinogen concentrate
46 Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome: A Pilot Study Recruiting NCT04053452
47 Early Prediction of Respiratory and Autonomic Complications of GBS Using Neuromuscular Ultrasound Recruiting NCT04166357
48 Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity Recruiting NCT03941184
49 Neurology Inpatient Clinical Education Trial Recruiting NCT03826056
50 Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia Recruiting NCT03206541

Search NIH Clinical Center for Guillain-Barre Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Immunoglobulins, Intravenous

Cochrane evidence based reviews: guillain-barre syndrome

Genetic Tests for Guillain-Barre Syndrome

Anatomical Context for Guillain-Barre Syndrome

MalaCards organs/tissues related to Guillain-Barre Syndrome:

40
Brain, T Cells, Spinal Cord, Testes, Heart, Lung, Eye

Publications for Guillain-Barre Syndrome

Articles related to Guillain-Barre Syndrome:

(show top 50) (show all 8434)
# Title Authors PMID Year
1
Guillain-Barre syndrome and its correlation with dengue, Zika and chikungunya viruses infection based on a literature review of reported cases in Brazil. 61 42
31220435 2019
2
Acute Fulminant Uremic Neuropathy Following Coronary Angiography Mimicking Guillain Barre Syndrome. 61 42
31562732 2019
3
Guillain-barre Syndrome in Indian Population: A Retrospective Study. 61 42
31309800 2019
4
Treatment-related Fluctuations in Guillain Barre Syndrome and the Conundrum of Additional Cycles of Plasmapheresis. 61 52
29184340 2017
5
Hypocretin/orexin and narcolepsy: new basic and clinical insights. 54 61
19555382 2010
6
[Evaluation of myelin basic protein levels with receiver operating characteristic curves for diagnosis of multiple sclerosis]. 54 61
19246291 2009
7
Guillain-Barré syndrome. 54 61
16271648 2005
8
T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. 54 61
16170091 2005
9
Hypocretins (orexins): clinical impact of the discovery of a neurotransmitter. 54 61
15979356 2005
10
Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome. 54 61
14653854 2004
11
Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy. 54 61
12676332 2003
12
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. 54 61
11912115 2002
13
CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. 54 61
11756606 2001
14
Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies. 54 61
11438177 2001
15
Anti-alpha B-crystallin immunoreactivity in inflammatory nervous system diseases. 54 61
11200685 2000
16
Anti-PMP22 antibodies in patients with inflammatory neuropathy. 54 61
10713353 2000
17
[Antiganglioside antibodies in the pathogenesis of autoimmune neuropathies]. 54 61
10377820 1999
18
T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barré syndrome. 54 61
9455979 1997
19
Soluble complement receptor type 1 in serum and cerebrospinal fluid of patients with Guillain-Barré syndrome and multiple sclerosis. 54 61
8707926 1996
20
[Anti-glycoconjugate antibodies and dysglobulinemic or dysimmune peripheral neuropathies]. 54 61
8881439 1996
21
Anti-alpha- and beta-tubulin IgM antibodies in dysimmune neuropathies. 54 61
8583236 1995
22
Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release. 54 61
7905957 1994
23
Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. 54 61
7689591 1993
24
T cell responses to myelin proteins in Guillain-Barré syndrome. 54 61
1279128 1992
25
In vitro demyelination by serum antibody from patients with Guillain-Barré syndrome requires terminal complement complexes. 54 61
1718212 1991
26
Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain-Barré syndrome and systemic lupus erythematosus. 54 61
2094193 1990
27
Antibodies to gangliosides and myelin proteins in Guillain-Barré syndrome. 54 61
2194427 1990
28
Zika virus promotes CCN1 expression via the CaMKIIα-CREB pathway in astrocytes. 61
31957543 2020
29
Six-month prospective study of quality of life in Guillain-Barre syndrome. 61
31705530 2020
30
Guillain-Barré Syndrome in a Teenage Girl: A Severe Case With Anti-GM2 Antibodies Associated With Acute CMV Infection and Literature Review. 61
31888351 2020
31
Tumor necrosis factor alpha -863C/A polymorphism and Guillain-Barré Syndrome. 61
31869721 2020
32
Plasma Exchange-Intravenous Immunoglobulin Synergy in the Treatment of Guillain-Barré Syndrome. 61
32008481 2020
33
Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related adverse reactions in the nervous system. 61
31823509 2020
34
The Dynamic Expression of Canonical Wnt/β-catenin Signalling Pathway in the Pathologic Process of Experimental Autoimmune Neuritis. 61
32009498 2020
35
Guillain-Barré syndrome: looking back… and forward. 61
31924731 2020
36
An Oculopharyngeal Subtype of Guillain-Barré Syndrome Sparing the Trochlear and Abducens Nerves. 61
32023583 2020
37
Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review. 61
31760541 2020
38
Benzenesulfonamide Derivatives as Calcium/Calmodulin-Dependent Protein Kinase Inhibitors and Antiviral Agents against Dengue and Zika Virus Infections. 61
31972088 2020
39
Cephalotaxine inhibits Zika infection by impeding viral replication and stability. 61
31818462 2020
40
Zika virus: an emerging challenge to public health worldwide. 61
31682478 2020
41
Successful treatment of a 12-year-old boy with Guillain-Barré syndrome requiring tracheostomy due to respiratory muscle paralysis: A case report. 61
32010274 2020
42
Cardiovascular complications and its relationship with functional outcomes in Guillain-Barré syndrome. 61
31504947 2020
43
The effects of IVIg therapy on serum levels of neuropeptide Y and cytokines in Guillain-Barré syndrome. 61
31494821 2020
44
Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. 61
31586949 2020
45
[Heavy metals in the enviroment: Guillain-Barre like syndrome]. 61
31984709 2020
46
Autonomic Hyperactivity. 61
31996626 2020
47
Guillain-Barré Syndrome During Platinum-Based Chemotherapy: A Case Series and Review of the Literature. 61
31615948 2020
48
Seizure in a Child with Guillain-Barré Syndrome: Association or coincidence! 61
31937711 2020
49
Serial single breath count is a reliable tool for monitoring respiratory functions in Guillain-Barré Syndrome. 61
31982274 2020
50
Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. 61
31981368 2020

Variations for Guillain-Barre Syndrome

Expression for Guillain-Barre Syndrome

Search GEO for disease gene expression data for Guillain-Barre Syndrome.

Pathways for Guillain-Barre Syndrome

Pathways related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.66 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 FAS
2 12.63 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 FAS
3
Show member pathways
12.59 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 FAS CD40LG
4 12.35 TNFRSF1B TNF FAS CD79A CD40LG
5
Show member pathways
12.23 HLA-DRB1 HLA-DQB1 HLA-DQA1 CD40LG
6 12.14 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1
7 12.05 TNFRSF1B TNF FAS CD40LG
8 12.01 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1
9
Show member pathways
11.83 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 CD40LG
10
Show member pathways
11.72 TNFRSF1B TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 CD79A
11 11.62 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1
12
Show member pathways
11.56 TNFRSF1B TNF CD40LG
13 11.54 HLA-DRB1 HLA-DQB1 HLA-DQA1
14
Show member pathways
11.54 HLA-DRB1 HLA-DQB1 HLA-DQA1
15 11.53 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1
16 11.52 MPZ HLA-DRB1 HLA-DQB1 HLA-DQA1 CD40LG

GO Terms for Guillain-Barre Syndrome

Cellular components related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.8 TNF MOG HLA-DRB1 CD79A CD40LG
2 membrane raft GO:0045121 9.78 TNFRSF1B TNF FAS CD79A
3 endocytic vesicle membrane GO:0030666 9.63 HLA-DRB1 HLA-DQB1 HLA-DQA1
4 ER to Golgi transport vesicle membrane GO:0012507 9.61 HLA-DRB1 HLA-DQB1 HLA-DQA1
5 transport vesicle membrane GO:0030658 9.54 HLA-DRB1 HLA-DQB1 HLA-DQA1
6 myelin sheath GO:0043209 9.43 PMP2 MPZ MBP
7 clathrin-coated endocytic vesicle membrane GO:0030669 9.33 HLA-DRB1 HLA-DQB1 HLA-DQA1
8 compact myelin GO:0043218 9.32 PMP22 MBP
9 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-DRB1 HLA-DQB1 HLA-DQA1
10 MHC class II protein complex GO:0042613 8.8 HLA-DRB1 HLA-DQB1 HLA-DQA1

Biological processes related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.84 PMP22 MPZ MBP HCRT
2 T cell receptor signaling pathway GO:0050852 9.71 MOG HLA-DRB1 HLA-DQB1 HLA-DQA1
3 interferon-gamma-mediated signaling pathway GO:0060333 9.69 HLA-DRB1 HLA-DQB1 HLA-DQA1
4 myelination GO:0042552 9.65 PMP22 MPZ MBP
5 response to salt stress GO:0009651 9.52 TNF TH
6 extrinsic apoptotic signaling pathway GO:0097191 9.5 TNFRSF1B TNF FAS
7 cellular response to nicotine GO:0071316 9.49 TNF TH
8 necroptotic signaling pathway GO:0097527 9.46 TNF FAS
9 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.43 HLA-DRB1 HLA-DQB1
10 antigen processing and presentation GO:0019882 9.43 HLA-DRB1 HLA-DQB1 HLA-DQA1
11 regulation of immunoglobulin secretion GO:0051023 9.37 TNF CD40LG
12 immune response GO:0006955 9.23 TNFRSF1B TNF MBP HLA-DRB1 HLA-DQB1 HLA-DQA1
13 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.16 HLA-DRB1 HLA-DQB1
14 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.13 HLA-DRB1 HLA-DQB1 HLA-DQA1

Molecular functions related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.13 HLA-DRB1 HLA-DQB1 HLA-DQA1
2 MHC class II receptor activity GO:0032395 8.8 HLA-DRB1 HLA-DQB1 HLA-DQA1

Sources for Guillain-Barre Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....